Form 4: NewAmsterdam Pharma Co N.V. Executive Kling Exercises Options and Sells Shares
SEC Form 4
Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., executed options to acquire 100,000 ordinary shares and subsequently sold them, along with other shares, under a pre-arranged trading plan.
Summary
- On May 15, 2025, Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., exercised options to acquire 100,000 ordinary shares at a price of $10 per share.
- Simultaneously, Kling sold 100,000 ordinary shares and another 44,000 shares in multiple transactions at prices ranging from $18.38 to $18.89 per share.
- Following these transactions, Kling directly owns 44,000 ordinary shares.
- The option was granted on November 22, 2022, and vests in equal monthly installments over four years.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a standard disclosure of stock transactions by an executive, which doesn't inherently indicate positive or negative sentiment about the company's future.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment about the company's prospects, although sales can be driven by various personal financial planning reasons.
Comparison to Industry Standards
- Insider trading disclosures are standard practice and regulated by the SEC.
- The Rule 10b5-1 trading plan is a common tool used by executives to avoid accusations of trading on inside information.
- Comparable companies like Amgen, Regeneron, and Vertex Pharmaceuticals also have executives who regularly file Form 4s related to stock options and sales.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The filing provides transparency to stakeholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 11/22/2022 | Option grant date |
| 12/22/2022 | First vesting date of the option (1/48th of shares) |
| 05/15/2025 | Transaction date: Option exercise and share sales |
| 05/19/2025 | Date of Form 4 filing |
| 11/22/2032 | Option expiration date |
Keywords
Form 4, Beneficial Ownership, Insider Trading, Douglas F. Kling, NewAmsterdam Pharma, NAMS, Options, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.